Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16345634 | 0.81 | TRPV6 (0.48) | HRH3TRPV6CYP11B1KCNH2CACNA1I | |
| SCHEMBL29725196 | 0.80 | HRH3 (0.56) | HRH3TRPV6CYP11B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1822660 | 0.80 | HRH3 (0.56) | HRH3TRPV6CYP11B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16441379 | 0.78 | TRPV6 (0.49) | TRPV6CYP11B1KCNH2CACNA1IGRM2 | |
| SCHEMBL29725200 | 0.78 | HRH3 (0.55) | HRH3TRPV6CYP11B1KCNH2CACNA1I | |
| SCHEMBL3869875 | 0.78 | HRH3 (0.55) | HRH3TRPV6CYP11B1KCNH2CACNA1I | |
| Hydrochloric Acid SCHEMBL4610066 | 0.78 | HRH3 (0.46) | HRH3TMEM97SIGMAR1SMN1; SMN2TSHR | |
| SCHEMBL31093419 | 0.77 | HRH3 (0.59) | HRH3TRPV6CYP11B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1858355 | 0.77 | HRH3 (0.59) | HRH3TRPV6CYP11B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL29695798 | 0.75 | CHRNB2 (0.55) | SMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | HRH3 482/4885TRPV6 302/4885HPGD 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.